Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss unmet needs in second-line non–small cell lung cancer.
Back
Exploring IB6 as a Therapeutic Target in Non–Small Cell Lung Cancer
Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the rationale for investigating IB6 as a therapeutic target in lung cancer.
Exploring IB6 as a Therapeutic Target in Non–Small Cell Lung Cancer
Episodes
All
All
Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the rationale for evaluating IB6 as a target in non–small cell lung cancer.
Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin in nonsquamous NSCLC.
Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin plus pembrolizumab in NSCLC.
Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss novel biomarkers under investigation in advanced NSCLC.
Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss unmet needs in advanced NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
4
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
5